Key Points
- CEO Bradley Campbell sold 75,000 shares on Jan. 20 at an average price of $14.31 for proceeds of $1.07 million, trimming his stake by 6.84% to 1,021,180 shares (worth about $14.6 million).
- Amicus recently beat quarterly EPS and revenue estimates with revenue up 19.5% year‑over‑year, but still has a negative net margin; analysts have trimmed ratings and targets—consensus is a "Hold" with an average target of $15.55.
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the transaction, the chief executive officer owned 1,021,180 shares of the company's stock, valued at $14,613,085.80. This represents a 6.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Amicus Therapeutics Stock Performance
NASDAQ FOLD opened at $14.27 on Friday. The firm has a market cap of $4.40 billion, a P/E ratio of -356.66 and a beta of 0.42. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70. The company's 50 day moving average is $12.13 and its 200-day moving average is $9.21. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $14.38.
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.05. The business had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. Amicus Therapeutics's revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 EPS. Sell-side analysts predict that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.
Analysts Set New Price Targets
FOLD has been the subject of several analyst reports. Jefferies Financial Group restated a "hold" rating and issued a $14.50 target price (down previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday. Citigroup reissued a "neutral" rating and issued a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Cantor Fitzgerald cut shares of Amicus Therapeutics from an "overweight" rating to a "hold" rating and reduced their price objective for the company from $21.00 to $14.50 in a research note on Friday, December 19th. Leerink Partners lowered shares of Amicus Therapeutics from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $17.00 to $14.50 in a report on Monday, December 29th. Finally, Guggenheim cut shares of Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $15.55.
View Our Latest Report on Amicus Therapeutics
Institutional Investors Weigh In On Amicus Therapeutics
Several hedge funds have recently bought and sold shares of the stock. Osaic Holdings Inc. grew its stake in Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 3,677 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Amicus Therapeutics by 167.1% during the 4th quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 1,243 shares during the last quarter. Strs Ohio purchased a new position in Amicus Therapeutics in the first quarter worth $30,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in Amicus Therapeutics in the third quarter valued at $31,000.
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.
The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
